One of the UK’s leading development stage pharmaceutical companies, Vernalis takes promising product candidates along a commercially-focused path to market. We derive pipeline candidates both from successful collaborations with a number of global pharmaceutical businesses and our own research activities. Our pipeline reflects our strategy and is split between our later stage commercial pipeline and our NCE portfolio.
The strategy is to:
- Build a profitable and cash generative business
- Develop and commercialise low-risk late stage products for unmet medical need
- Partner all of our drug candidates; selective investment in our in-house products